nslational Breast Cancer Research Consortium was well represented at the 2014 ASCO Meeting.  Presentations included:

Whole-Exome Sequencing (WES) of HER2+ Metastatic Breast Cancer (MBC) from Patients Treated with Prior Trastuzumab: A Correlative Analysis of TBCRC003; Abstract #536

Identification of Biomarkers to Predict Response to Single-Agent Platinum Chemotherapy in Metastatic TNBC: Correlative Studies from TBCRC009; Abstract #1020

TBCRC 022:Phase II Trial of Neratinib for Patients with HER2+ Breast Cancer Brain Metastases (BCBM); Abstract # 528

TBCRC 028: A Phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in Combination with Cisplatin in Metastatic Androgen Receptor Negative Triple Negative Breast Cancer (TNBC); Abstract # TPS1148

TBCRC 030: A Randomized, Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with BRCA1/2-proficient Triple Negative Breast Cancer (TNBC): Evaluating the Homologous Recombination Deficiency (HRD) Biomarker; Abstract #TPS1145